Beta2-Adrenergic Receptor Gene Polymorphisms. Will the Important One Please Step Forward?

Journal of the American College of Cardiology

Volumn 52, Issue 17, 2008, Pages 1389-1390

  Michel, Martin C ^a   Büscher, Rainer ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

beta2 adrenergic receptor; single nucleotide polymorphism; vasodilation

Indexed keywords

ARGININE; BETA 2 ADRENERGIC RECEPTOR; GLUTAMIC ACID; GLUTAMINE; GLYCINE; ISOLEUCINE; TERBUTALINE; THREONINE;

AMINO ACID SUBSTITUTION; ARTERY DISEASE; CHROMOSOME 5Q; CORONARY ARTERY DISEASE; CYSTIC FIBROSIS; DNA POLYMORPHISM; EDITORIAL; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HEART FAILURE; HEART RATE; HUMAN; HYPERTENSION; NONHUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; NOTE; PERIPHERAL VASCULAR DISEASE; VASODILATATION;

CORONARY ARTERY DISEASE; HUMANS; PERIPHERAL VASCULAR DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, BETA-2; VASODILATION;

EID: 53449099576     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.07.040     Document Type: Editorial

References (22)

1. Brodde O.-E. β-1 and β-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses. Pharmacol Ther 117 (2008) 1-29
2. 2-adrenoceptor gene and hypertension: is it the promoter or the coding region or neither?. J Hypertension 24 (2006) 1003-1007
3. Rosskopf D., Schürks M., Rimmbach C., and Schäfers R.F. Genetics of arterial hypertension and hypotension. Naunyn Schmiedebergs Arch Pharmacol 374 (2007) 429-469
4. 2-adrenergic receptor gene on coronary artery disease. J Am Coll Cardiol 52 (2008) 1381-1388
5. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 268 (1993) 23116-23121
6. 2-adrenergic receptor overexpression. A novel role for the endothelial adrenergic system. Circ Res 97 (2005) 1182-1189
7. 2 adrenoceptor gene Thr164Ile polymorphism on human adipose tissue lipolytic function. Br J Pharmacol 133 (2001) 708-712
8. Büscher R., Eilmes K.J., Grasemann H., et al. β2 adrenoceptor gene polymorphisms in cystic fibrosis lung disease. Pharmacogenetics 12 (2002) 347-353
9. 2-adrenoceptor on the effects of β-adrenoceptor agonists on human lung mast cells. Int Immunopharmacol 3 (2003) 91-95
10. 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci U S A 93 (1996) 10483-10488
11. 2-adrenergic receptor gene is associated with risk of elevated blood pressure in women. The Copenhagen City Heart Study. Pharmacogenet Genomics 15 (2005) 633-645
12. 2 adrenergic receptor increases the risk of cardiac hypertrophy in hypertension. J Hypertension 22 (2004) 2117-2122
13. 2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 102 (1998) 1534-1539
14. 2-adrenergic receptor negatively modulates cardiac contractility: implications for prognosis of patients with idiopathic dilated cardiomyopathy. Heart 93 (2007) 856-861
15. Forleo C., Resta N., Sorrentino S., et al. Association of β-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med 117 (2004) 451-458
16. De Groote P., Lamblin N., Helbecque N., et al. The impact of beta-adrenoceptor gene polymorphisms on survival in patients with congestive heart failure. Eur J Heart Fail 7 (2005) 966-973
17. Brodde O.-E., and Michel M.C. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 51 (1999) 651-689
18. 2-adrenoceptors. Circulation 103 (2001) 1048-1050
19. 2-adrenoceptor exhibits blunted desensitization of cardiac functional responses in vivo. Am J Physiol 285 (2003) H2034-H2038
20. 2-adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo. Pharmacogenetics 14 (2004) 517-522
21. 2-adrenergic receptor gene haplotypes and venodilation in vivo. Clin Pharmacol Ther 78 (2005) 232-238
22. Büscher R., and Grasemann H. Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?. Naunyn Schmiedebergs Arch Pharmacol 374 (2006) 65-77